EP1871769

CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE.

  • :
    EP einkaleyfi: Þýðing ekki lögð inn
  • :
    14.12.2005
  • :
    22.2.2017
  • :
    05818127.2
  • :
    13.12.2025
  • :
    CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE.

14.12.2005
22.2.2017
  • :
    AstraZeneca AB
  • :
    151 85 Södertälje, SE
  • :
    FORD, James GairAstraZeneca
  • :
    MacclesfieldCheshire SK10 2NA, GB
  • :
    MCCABE, James FrancisAstraZeneca
  • :
    MacclesfieldCheshire SK10 2NA, GB
  • :
    O'KEARNEY-MCMULLAN, AnneAstraZeneca
  • :
    MacclesfieldCheshire SK10 2NA, GB
  • :
    O'KEEFE, PhilipAstraZeneca R & D Charnwood
  • :
    LoughboroughLeicestershire LE11 5RH, GB
  • :
    POINTON, Simon MarkAstraZeneca
  • :
    Maccl esfieldCheshire SK10 2NA, GB
  • :
    POWELL, LynAstraZeneca
  • :
    MacclesfieldCheshire SK10 2NA, GB
  • :
    PURDIE, MarkAstraZeneca R & D Charnwood
  • :
    LoughboroughLeicestershire LE11 5RH, GB
  • :
    WITHNALL, JaneAstraZeneca R & D Charnwood
  • :
    LoughboroughLeicestershire LE11 5RH, GB
  • :
    0427697
  • :
    17.12.2004
  • :
    GB
  • :
    GB2005004807
  • :
    14.12.2005
  • :
    C07D 405/12, A61K 31/517